Veru Inc.

VERU

US92536C1036

Personal Products

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-16 EDT			5-day change	1st Jan Change
1.04 ^USD	+9.29%		+24.63%	+44.44%

07-01	Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Comp Value Index	CI
07-01	Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Completeness Index	CI

The Female Health Company Provides Earnings Guidance for the Year 2013

January 30, 2013 at 08:30 am

The Female Health Company provided earnings guidance for the year 2013. For the year 2013, the company expects continued revenue and operating income growth.

Latest news about Veru Inc.

Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Comp Value Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Completeness Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2000 Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000E Value Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000 Growth Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000E Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2500 Value Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000 Value Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2000 Value Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000E Growth Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2000 Growth Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2000 Dynamic Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell Microcap Value Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2500 Growth Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Comp Growth Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2500 Index	06-30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000 Index	06-30	CI
Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference	05-22	CI
B. Riley Securities Starts Very With Buy Rating, $5 Price Target	05-14	MT
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-08	CI
Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	05-08	MT
Transcript : Veru Inc., Q2 2024 Earnings Call, May 08, 2024	05-08
HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	05-06	MT
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	04-30	CI
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	04-15	MT

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Sector

Personal Products

Calendar

2024-08-07 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Veru Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.04 USD

Average target price

3.44 USD

Spread / Average Target

+230.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Birth Control Products

	1st Jan change	Capi.
VERU INC.	+44.44%	139M
CUPID LIMITED	+56.39%	282M
KAREX	+15.75%	192M
THAI NIPPON RUBBER INDUSTRY PUBLIC CO., LTD.	+16.49%	93.84M
SAGAMI RUBBER INDUSTRIES CO., LTD.	+13.90%	70.7M

Birth Control Products

Veru Inc.

Equities

VERU

US92536C1036

Personal Products

The Female Health Company Provides Earnings Guidance for the Year 2013

Latest news about Veru Inc.

Chart Veru Inc.

Company Profile

Income Statement Evolution

Ratings for Veru Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Birth Control Products